Biomea Fusion reports Q1 earnings miss, mixed analyst opinions, and varying price targets.
Biomea Fusion, a clinical-stage biopharmaceutical company, has experienced mixed analyst opinions with lowered price targets from Barclays and Scotiabank, while JPMorgan Chase & Co. and HC Wainwright maintain neutral or positive ratings. The consensus rating for Biomea Fusion is "Moderate Buy" with a consensus price target of $28.25. The company reported a Q1 earnings miss with an EPS of ($1.09) compared to analyst estimates of ($1.02).
June 10, 2024
4 Articles